» Articles » PMID: 37162624

Quality of Life in Chronic Venous Disease: Bridging the Gap Between Patients and Physicians

Overview
Date 2023 May 10
PMID 37162624
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic venous disease (CVD) has a negative impact on patients' quality of life (QoL). This was demonstrated in the recent Patient Journey on CVD study, which examined QoL in patients with early- and advanced-stage CVD (Clinical, Etiological, Anatomical and Pathophysiological classification C0 to C4), and the gaps between the way in which physicians and patients viewed the impact of CVD on QoL. The study was conducted in five countries (Brazil, China, Czech Republic, Italy and Russia) and included 100 patients with CVD and 60 CVD specialists. Patients completed the 14-item Chronic Venous Insufficiency Questionnaire (CIVIQ-14) to assess their QoL, and all patients and physicians were questioned during a 60-minute qualitative structured interview, focusing on four key dimensions-physical symptoms, aesthetics/appearance, emotional impact and impact on relationships. The study found that physicians tended to focus more on physical symptoms than on other impacts of CVD and rarely measured QoL in clinical practice. Patients were significantly less satisfied with the management of their QoL than physicians perceived them to be. About 25% of patients with CVD reported disturbed sleep, but physicians did not routinely ask them how CVD affected their sleep. These data reinforce the importance of physicians obtaining information about the impact of CVD on all aspects of the patient's life, including sleep and QoL. Evidence from randomised controlled trials and real-world studies demonstrates that some veno-active drugs, particularly micronised purified flavonoid fraction, can positively impact QoL in patients with CVD.

Citing Articles

The Impact of Inflammatory Markers and Obesity in Chronic Venous Disease.

Petrascu F, Matei S, Margan M, Ungureanu A, Olteanu G, Murariu M Biomedicines. 2024; 12(11).

PMID: 39595090 PMC: 11592460. DOI: 10.3390/biomedicines12112524.


Network Pharmacology Approaches Used to Identify Therapeutic Molecules for Chronic Venous Disease Based on Potential miRNA Biomarkers.

Barrera-Vazquez O, Escobar-Ramirez J, Magos-Guerrero G J Xenobiot. 2024; 14(4):1519-1540.

PMID: 39449424 PMC: 11503387. DOI: 10.3390/jox14040083.


Strategies to reduce rates of severe endothermal heat-induced thrombosis following radiofrequency ablation.

Kedwai B, Geiger J, Lehane D, Glocker R, Newhall K, Pitcher G J Vasc Surg Venous Lymphat Disord. 2024; 12(4):101864.

PMID: 38518986 PMC: 11523318. DOI: 10.1016/j.jvsv.2024.101864.


Effectiveness of Sclerotherapy to Cure Lower Limb Chronic Venous Insufficiency Grades 1-6: A Systematic Review and Meta-Analysis.

Dewi D, Arimuko A, Norawati L, Dewi R, Wiraguna A, Allatib A Cureus. 2024; 15(12):e49770.

PMID: 38164304 PMC: 10758268. DOI: 10.7759/cureus.49770.


Foreword.

Maleti O Clin Drug Investig. 2023; 43(Suppl 1):1-2.

PMID: 37173529 PMC: 10220093. DOI: 10.1007/s40261-023-01262-x.

References
1.
Kakkos S, Nicolaides A . Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled.... Int Angiol. 2018; 37(2):143-154. DOI: 10.23736/S0392-9590.18.03975-5. View

2.
Martinez-Zapata M, Vernooij R, Simancas-Racines D, Uriona Tuma S, Stein A, Moreno Carriles R . Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020; 11:CD003229. PMC: 8094625. DOI: 10.1002/14651858.CD003229.pub4. View

3.
Guex J, Enriquez Vega D, Avril L, Boussetta S, Taieb C . Assessment of quality of life in Mexican patients suffering from chronic venous disorder - impact of oral Ruscus aculeatus-hesperidin-methyl-chalcone-ascorbic acid treatment - 'QUALITY Study'. Phlebology. 2009; 24(4):157-65. DOI: 10.1258/phleb.2009.008066. View

4.
Heit J, Rooke T, Silverstein M, Mohr D, Lohse C, Petterson T . Trends in the incidence of venous stasis syndrome and venous ulcer: a 25-year population-based study. J Vasc Surg. 2001; 33(5):1022-7. DOI: 10.1067/mva.2001.113308. View

5.
Santiago F, Ulloa J, Regnier C, Peudon T, Braund E, Fradet-Aubignat C . The impact of lower limb chronic venous disease on quality of life: patient and physician perspectives. J Comp Eff Res. 2022; 11(11):789-803. DOI: 10.2217/cer-2022-0054. View